CAI — Caris Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $10.40bn
- $10.06bn
- $412.26m
- 45
- 11
- 66
- 35
Annual cashflow statement for Caris Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -341 | -282 |
| Depreciation | ||
| Non-Cash Items | 23.4 | 16.8 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -7.13 | -29.1 |
| Change in Accounts Receivable | ||
| Change in Inventories | ||
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Cash from Operating Activities | -276 | -245 |
| Capital Expenditures | -22.3 | -8.44 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 237 | 61.4 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 215 | 52.9 |
| Financing Cash Flow Items | -2.3 | -1.06 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 10.1 | 200 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -51.1 | 8.02 |